<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648048</url>
  </required_header>
  <id_info>
    <org_study_id>GB29764</org_study_id>
    <secondary_id>2015-003481-81</secondary_id>
    <nct_id>NCT02648048</nct_id>
  </id_info>
  <brief_title>A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>ISLAND2</acronym>
  <official_title>A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and
      tolerability of vismodegib in combination with pirfenidone in participants with idiopathic
      pulmonary fibrosis (IPF) currently being treated with pirfenidone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Baseline up to 28 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship. A serious adverse event is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Discontinuation of Any Study Medication Due to a Drug-Related Adverse Event</measure>
    <time_frame>Baseline up to 28 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship. Relatedness to the study drug will be assessed by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose Modifications Due to Laboratory Abnormalities and Adverse Events</measure>
    <time_frame>Baseline up to 28 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Clinically Meaningful Laboratory Abnormalities as Assessed by Investigator</measure>
    <time_frame>Baseline up to 28 weeks</time_frame>
    <description>Vital signs and laboratory parameters will be evaluated, and percentage of participants with any clinically meaningful abnormalities as assessed by Investigator will be reported. Laboratory abnormalities of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than (&gt;) 3 will be considered clinical meaningful.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total and Free Trough Plasma Concentrations of Vismodegib at Week 4 (Cmin, Wk4)</measure>
    <time_frame>Predose (0 hour) at Week 4</time_frame>
    <description>Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + alpha-1-acid glycoprotein (AAG)-bound vismodegib plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and Free Trough Plasma Concentrations of Vismodegib at Week 12 (Cmin, Wk12)</measure>
    <time_frame>Predose (0 hour) at Week 12</time_frame>
    <description>Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and Free Trough Plasma Concentrations of Vismodegib at Week 24 (Cmin, Wk24)</measure>
    <time_frame>Predose (0 hour) at Week 24</time_frame>
    <description>Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and Free Trough Plasma Concentrations of Vismodegib at Safety Follow-up Visit (Cmin, SFU)</measure>
    <time_frame>At Day 30 post last dose (last dose = 24 weeks) (up to 28 weeks)</time_frame>
    <description>Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Vismodegib and Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone will be administered as per the dosage schedule mentioned in arm description.</description>
    <arm_group_label>Vismodegib and Pirfenidone</arm_group_label>
    <other_name>RO0220912</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Vismodegib will be administered as per the dosage schedule mentioned in arm description.</description>
    <arm_group_label>Vismodegib and Pirfenidone</arm_group_label>
    <other_name>RO5450815</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of IPF 5 years from time of screening, confirmed at baseline

          -  Tolerated dose of pirfenidone 1602-2403 mg once daily (QD) for a minimum of 24 weeks
             required prior to and during screening

          -  Greater than or equal to (&gt;=) 50 percent (%) and less than or equal to (&lt;=) 100% of
             predicted forced vital capacity (FVC) at screening

          -  Stable baseline lung function as evidenced by a difference of less than (&lt;) 10% in
             absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to
             enrollment

          -  &gt;=30% and &lt;=90% of predicted diffusion capacity of the lung for carbon monoxide at
             screening

          -  Agree to use protocol defined methods of contraception

          -  Male participants must agree not to donate semen during the study and for at least 2
             months (or as per local requirements) after the last dose of vismodegib

          -  Agree not to donate blood or blood products during the study and for at least 9 months
             (or as per local requirements) after the last dose of study treatment

        Exclusion Criteria:

          -  Prior treatment with vismodegib or any Hh-pathway inhibitor

          -  Evidence of other known causes of interstitial lung disease

          -  Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during
             screening

          -  Lung transplant expected within 6 months of screening

          -  Evidence of clinically significant lung disease other than IPF

          -  Post-bronchodilator forced expiratory volume in 1 second/FVC ratio &lt;0.7 at screening

          -  Any clinically significant medical disease (other than IPF) that is associated with an
             expected survival of &lt;6 months, likely to require a change in therapy during the study

          -  Class IV New York Heart Association chronic heart failure or historical evidence of
             left ventricular ejection fraction &lt;35%

          -  Known current malignancy or current evaluation for a potential malignancy

          -  Known immunodeficiency, including, but not limited to, human immunodeficiency virus
             infection

          -  Evidence of acute or chronic hepatitis or known liver cirrhosis

          -  Creatinine clearance &lt;=30 milliliter per minute, calculated using the Cockcroft-Gault
             formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Lung Associates</name>
      <address>
        <city>Elk Grove</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, PC ; Pulmonary</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-1798</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Research</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Respiratory Institute</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonix LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Washington Medical Group</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraunhofer-Institut fur Toxikologie und Experimentelle Medizin ITEM</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Vismodegib</keyword>
  <keyword>Pirfenidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

